Cellectis SA
ALCLS
Company Profile
Business description
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Contact
8, rue de la Croix Jarry
Paris75013
FRAT: +33 181691600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
222
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,561.70 | 142.70 | -1.85% |
| CAC 40 | 7,100.42 | 173.30 | 2.50% |
| DAX 40 | 20,280.26 | 490.64 | 2.48% |
| Dow JONES (US) | 37,615.47 | 2,930.46 | -7.23% |
| FTSE 100 | 7,910.53 | 208.45 | 2.71% |
| HKSE | 20,059.82 | 67.86 | -0.34% |
| NASDAQ | 15,267.91 | 1,282.69 | -7.75% |
| Nikkei 225 | 31,714.03 | 1,298.55 | -3.93% |
| NZX 50 Index | 11,806.55 | 84.89 | -0.71% |
| S&P 500 | 4,977.73 | 84.52 | -1.67% |
| S&P/ASX 200 | 7,375.00 | 135.00 | -1.80% |
| SSE Composite Index | 3,175.90 | 30.35 | 0.96% |